1 minute read
Mar. 14, 2023

Mavacamten: FDA Approved First-In-Class Allosteric Cardiac Myosin Inhibitor

Myokardia/BMS cardiac myosin inhibitor

FIC, oral, QD, cardiac myosin inhibitor FDA-approved for obstructive HCM opt. of HTS hit for sarcomere activity inhibition mavacamten (MYK461, CAMZYOS) Myokardia, Brisbane, CA; Bristol Myers Squibb, New York, NY


Molecules of the Month

MOTY Nominees

Molecule of the Year